Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase II study from a Chinese Center

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Huang, Chao Qun ^a   Yang, Xiao Jun ^a   Yu, Yang ^a   Wu, Hai Tao ^a   Liu, Yang ^a,b   Yonemura, Yutaka ^b   Li, Yan ^a  

^a WUHAN UNIVERSITY   (China)

^b NPO Organization to Support Peritoneal Dissemination Treatment   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHINA; CHINESE; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DELIRIUM; DIARRHEA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPOALBUMINEMIA; INTESTINAL BLEEDING; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; PERIOPERATIVE PERIOD; PERITONEAL CANCER INDEX; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PROSPECTIVE STUDY; SEPTICEMIA; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; CARCINOMA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; HYPERTHERMIC THERAPY; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHINA; CISPLATIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84907432718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108509     Document Type: Article

References (59)

1. Al-Shammaa HA, Li Y, Yonemura Y (2008) Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 14: 1159-1166. doi: 10.3748/wjg.14.1159.
2. Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, et al. (2012) Peritoneal carcinomatosis: cytoreductive surgery and HIPEC-overview and basics. Cancer Invest 30: 209-224. doi: 10.3109/07357907.2012.654871.
3. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, et al. (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88: 358-363. doi: 10.1002/(SICI)1097-0142(20000115)88:2〈358::AID-CNCR16〉3.0.CO;2-O.
4. Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89: 1545-1550. doi: 10.1046/j.1365-2168.2002.02274.x.
5. Glehen O, Osinsky D, Beaujard AC, Gilly FN (2003) Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12: 729-739,xiii. doi: 10.1016/S1055-3207(03)00044-9.
6. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, et al. (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 21: 3737-3743. doi: 10.1200/JCO.2003.04.187.
7. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, et al. (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22: 3284-3292. doi: 10.1200/JCO.2004.10.012.
8. Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16: 2152-2165. doi: 10.1245/s10434-009-0487-4.
9. Tang L, Mei LJ, Yang XJ, Huang CQ, Zhou YF, et al. (2011) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study. J Transl Med 9: 53. doi: 10.1186/1479-5876-9-53.
10. Yang XJ, Li Y, Hassan AHA, Yang GL, Liu SY, et al. (2009) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol 16: 345-351. doi: 10.1245/s10434-008-0226-2.
11. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, et al. (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18: 1575-1581. doi: 10.1245/s10434-011-1631-5.
12. Huang CQ, Feng JP, Yang XJ, Li Y (2014) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center. J Surg Oncol 109: 730-739. doi: 10.1002/jso.23545.
13. Sugarbaker PH (2001) Cytoreduction surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27: 239-243. doi: 10.1053/ejso.2000.1038.
14. Fujimoto S, Takahashi M, Koyabayashi K, Nagano K, Kure M, et al. (1992) Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer 70: 2754-2760. doi: 10.1002/1097-0142(19921215)70:12〈2754::AID-CNCR2820701205〉3.0.CO;2-A.
15. Sugarbaker PH (1999) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43(Suppl): S15-S25. doi: 10.1007/s002800051093.
16. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, et al. (2010) Carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28: 63-68. doi: 10.1200/JCO.2009.23.9285.
17. National Cancer Institute (nd) Common Terminology Criteria for Adverse Events version 4.0. Available: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 2014 Jan 11.
18. Li PC, Chen LD, Zheng F, Li Y (2008) Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study. J Cancer Res Clin Oncol 134: 37-44. doi: 10.1007/s00432-007-0242-9.
19. Glehen O, Mohamed F, Gilly FN (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5: 219-228. doi: 10.1016/S1470-2045(04)01425-1.
20. Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, et al. (2001) Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37: 979-984. doi: 10.1016/S0959-8049(01)00058-2.
21. Stewart JH 4th, Shen P, Russell G, Fenstermaker J, McWilliams L, et al. (2008) A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 15: 2137-2145. doi: 10.1245/s10434-008-9967-1.
22. Harrison LE, Bryan M, Pliner L, Saunders T (2008) Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol 15: 1407-1413. doi: 10.1245/s10434-007-9718-8.
23. Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, et al. (2008) Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 5: 535-541. doi: 10.1245/s10434-007-9648-5.
24. Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, et al. (2011) Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol 18: 2599-2603. doi: 10.1245/s10434-011-1651-1.
25. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, et al. (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 21: 799-806. doi: 10.1200/JCO.2003.06.139.
26. Rouers A, Laurent S, Detroz B, Meurisse M (2006) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C. Acta Chir Belg 106: 302-306. PMID:16910003.
27. Elias D, Goere D, Blot F, Billard V, Pocard M, et al. (2007) Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 14: 1818-1824. doi: 10.1245/s10434-007-9348-1.
28. van Leeuwen BL, Graf W, Pahlman L, Mahteme H (2008) Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 15: 745-753. doi: 10.1245/s10434-007-9700-5.
29. Yan TD, Morris DL (2008) Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 248: 829-835. doi: 10.1097/SLA.0b013e31818a15b5.
30. Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, et al. (2009) Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg 52: 135-141. PMCID: PMC2663512.
31. Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, et al. (2011) Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 254: 294-301. doi: 10.1097/SLA.0b013e3182263933.
32. Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, et al. (2012) The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol 19: 2186-2194. doi: 10.1245/s10434-012-2264-z.
33. Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, et al. (2013) A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 7;13: 67. doi: 10.1186/1471-2407-13-67.
34. Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, et al. (2013) Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol. Ann Surg Oncol 20: 4224-4230. doi: 10.1245/s10434-013-3145-9.
35. Cavaliere F, De Simone M, Virzì S, Deraco M, Rossi CR, et al. (2011) Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 37: 148-154. doi: 10.1016/j.ejso.2010.10.014.
36. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82: 359-374. doi: 10.1007/978-1-4613-1247-5-23.
37. Maggiori L, Elias D (2010) Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 36: 599-603. doi: 10.1016/j.ejso.2010.05.007.
38. Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH (1996) Patterns of spread of recurrent intra-abdominal sarcoma. Cancer Treat Res 82: 65-77. doi: 10.1007/978-1-4613-1247-5-5.
39. da Silva RG, Sugarbaker PH (2006) Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 203: 878-886. doi: 10.1016/j.jamcollsurg.2006.08.024.
40. Saxena A, Yan TD, Chua TC, Morris DL (2010) Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 17: 1291-1301. doi: 10.1245/s10434-009-0875-9.
41. Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? : A systematic review of morbidity and mortality. Ann Surg 249: 900-907. doi: 10.1097/SLA.0b013e3181a45d86.
42. Mizumoto A, Canbay E, Hirano M, Takao N, Matsuda T, et al. (2012) Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at a Single Institution in Japan. Gastroenterol Res Pract 2012: 836425. doi: 10.1155/2012/836425.
43. Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89: 480-487. doi: 10.1093/jnci/89.7.480.
44. Nissan A, Guillem JG, Paty PB, Wong WD, Cohen AM (2004) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91: 747-754. doi: 10.1002/bjs.4473.
45. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, et al. (2007) Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14: 509-514. doi: 10.1245/s10434-006-9167-9.
46. Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27: 681-685. doi: 10.1200/JCO.2008.19.7160.
47. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, et al. (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116: 3756-3762. doi: 10.1002/cncr.25116.
48. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, et al. (2011) Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 18: 1560-1567. doi: 10.1245/s10434-010-1522-1.
49. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, et al. (2013) Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 16;108: 1432-1439. doi: 10.1038/bjc.2013.82.
50. Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89: 1545-1550. doi: 10.1046/j.1365-2168.2002.02274.x.
51. Whittemore AS, Wu-Williams AH, Lee M, Zheng S, Gallagher RP, et al. (1990) Diet, physical activity, and colorectal cancer among Chinese in North America and China. J Natl Cancer Inst 82: 915-926. doi: 10.1093/jnci/82.11.915.
52. Zheng S, Chen K, Liu X, Ma X, Yu H, et al. (2003) Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum 46: 51-58. doi: 10.1007/s10350-004-6496-2.
53. Fu JF, Huang YQ, Yang J, Yi CH, Chen HL, et al. (2013) Clinical characteristics and prognosis of young patients with colorectal cancer in Eastern China. World J Gastroenterol 19: 8078-8084. doi: 10.3748/wjg.v19.i44.8078.
54. Xu J, Zhong Y, Weixin N, Xinyu Q, Yanhan L, et al. (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245: 583-590. doi: 10.1007/s10350-004-6496-2.
55. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, et al. (2010) Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol 16: 960-965. doi: 10.3748/wjg.v16.i8.960
56. Zhang S, Cui Y, Weng Z, Gong X, Chen M, et al. (2009) Changes on the disease pattern of primary colorectal cancers in Southern China: a retrospective study of 20 years. Int J Colorectal Dis 24: 943-949. doi: 10.1007/s00384-009-0726-y.
57. Wang T, Cui Y, Huang WS, Deng YH, Gong W, et al. (2009) The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc 69: 609-615. doi: 10.1016/j.gie.2008.05.017.
58. Ho JW, Lam TH, Tse CW, Chiu LK, Lam HS, et al. (2004) Smoking, drinking and colorectal cancer in Hong Kong Chinese: a case-control study. Int J Cancer 109(4): 587-597. doi: 10.1002/ijc.20018.
59. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, et al. (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut. 61: 1439-1446. doi: 10.1136/gutjnl-2011-300843.